CLEVELAND (BUSINESS WIRE) Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14th World Stroke Con.
Athersys (ATHX) Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CLEVELAND (BUSINESS WIRE) $ATHX #ARS Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health.
Webinar scheduled for June 14, 2022 at 5:00 p.m. ETCLEVELAND (BUSINESS WIRE) $ATHX #investorconference Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a panel discussion with leading neurology experts.
Athersys Hosting KOL Panel Event to Discuss TREASURE Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.